Functional viability profiles of breast cancer.

@article{Brough2011FunctionalVP,
  title={Functional viability profiles of breast cancer.},
  author={Rachel Brough and Jessica R. Frankum and David Sims and Alan Mackay and Ana M. Mendes-Pereira and Ilirjana Bajrami and Sara Costa-Cabral and Rumana Rafiq and Amar S. Ahmad and Maria Antonietta Cerone and Rachael Natrajan and Rachel Sharpe and K-K. Shiu and D Wetterskog and Konstantin J. Dedes and Maryou B. K. Lambros and Teeara Rawjee and Spiros Linardopoulos and Jorge Sergio Reis-Filho and Nicholas C. Turner and Christopher J. Lord and Alan Ashworth},
  journal={Cancer discovery},
  year={2011},
  volume={1 3},
  pages={
          260-73
        }
}
UNLABELLED The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to discriminate between genes that are critical for maintaining the disease state and those that are merely coincidental. Even when critical genes can be identified, directly targeting these is often challenging, meaning that alternative strategies… Expand
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
TLDR
A methodology for generating uniform and reproducible tumor spheroids that can be subjected to siRNA functional screening and is able to further investigate and confirm the spatial impact of these dependencies using immunohistochemistry. Expand
Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
TLDR
Inhibition of the NUAK1 protein kinase by the small molecule drug HTH-01-015 selectively impaired viability in multiple PTEN-deficient breast cancer cell lines, while mutations affecting STK11 and PTEN were largely mutually exclusive across large pan-cancer data sets. Expand
Triple-negative breast cancer: investigating potential molecular therapeutic target
TLDR
The molecular alteration present in TNBC is investigated which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way. Expand
Applications of RNA Indexes for Precision Oncology in Breast Cancer
TLDR
The benefits of transcriptomic analyses in breast cancer management are summarized and it is proposed that unscrambling the core signaling networks of cancer may be an important task of multiple-omic data integration for precision oncology. Expand
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
TLDR
The finding that IBC cells are sensitive to HDAC6 inhibition provides a foundation to rapidly develop novel, efficient, and well-tolerated targeted therapy strategies for IBC patients. Expand
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
TLDR
Promising data now indicate that p90 ribosomal S6 kinase 2 (RSK2), a downstream member of the MAPK signaling pathway, is a validated target for TNBC and the challenge ahead is to develop RSK inhibitors that have favorable pharmacokinetic properties, which will allow for their evaluation in clinical trials for patients with TNBC. Expand
From integrative genomics to therapeutic targets.
TLDR
By focusing efforts on homogenous subgroups of breast cancer and integrating orthogonal data-types combined with functional approaches, the authors can begin to unravel the heterogeneity and identify aberrations that can be therapeutically targeted. Expand
Mining the Viability Profiles of Different Breast Cancer: A Soft Computing Perspective
TLDR
This work describes a methodology able to identify a small set of those mutations that affect in a differential way several breast cancer lines and shows that cancer lines can be profiled with only a small subset of mutations from an original list of hundreds of mutations. Expand
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
TLDR
The utility of siRNA screens to predict the drug sensitivity of genetically or histologically defined subsets of tumor cell lines, including an increased sensitivity of osteosarcoma cell lines to FGFR inhibitors and SMAD4 mutant tumor cells to mitotic inhibitors is demonstrated. Expand
Reviewing the somatic genetics of melanoma: from current to future analytical approaches
TLDR
This article will review the catalog of mutations identified in melanoma through a variety of approaches, including the use of unbiased exome and whole‐genome NGS platforms, as well discuss complementary strategies for identifying driver mutations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
TLDR
It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations. Expand
ROCK: a breast cancer functional genomics resource
TLDR
ROCK collates data from a wealth of breast cancer molecular profiling and functional screening studies into a single portal, where analysed and annotated results can be accessed at the level of a gene, sample or study, thus enhancing the discovery of novel targets and biomarkers for breast cancer. Expand
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
TLDR
A novel approach combining RNAi screening in multiple cell lines with gene expression and genomic profiling to identify novel cancer targets, allowing the identification of several novel kinases, including WEE1, that are essential for viability only in cell lines that have an elevated level of expression of this kinase. Expand
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
TLDR
Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups. Expand
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
TLDR
CDK10 is an important determinant of resistance to endocrine therapies and it is shown that CDK10 silencing increases ETS2-driven transcription of c-RAF, resulting in MAPK pathway activation and loss of tumor cell reliance upon estrogen signaling. Expand
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
TLDR
Genome-informed drug sensitivity studies identify a subset of GBMs likely to respond to CDK4/6 inhibition, and demonstrate that the integration of genomic, functional and pharmacologic data can be exploited to inform the development of targeted therapy directed against specific cancer pathways. Expand
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
TLDR
It is indicated that aberrant PI3K pathway signaling is strongly associated with metastasis and poor survival across carcinoma types, highlighting the enormous potential impact on patient survival that pathway inhibition could achieve. Expand
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
TLDR
The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options. Expand
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
TLDR
This proof‐of‐principle study provides direct evidence of intra‐tumour genetic heterogeneity in breast cancers, and shows that in some cases morphological diversity may be underpinned by distinct genetic aberrations. Expand
Cancer Proliferation Gene Discovery Through Functional Genomics
TLDR
A highly parallel multiplex methodology for screening large pools of shRNAs using half-hairpin barcodes for microarray deconvolution to identify cancer proliferation and survival genes for target discovery is described. Expand
...
1
2
3
4
5
...